

Review

Regulation of bacterial gene expression by non-coding RNA: It is all about time!

Adrien Chauvier¹ and Nils G. Walter^{1,*}

¹Single Molecule Analysis Group and Center for RNA Biomedicine, Department of Chemistry, University of Michigan, Ann Arbor, MI, USA

*Correspondence: nwalter@umich.edu

<https://doi.org/10.1016/j.chembiol.2023.12.011>

SUMMARY

Commensal and pathogenic bacteria continuously evolve to survive in diverse ecological niches by efficiently coordinating gene expression levels in their ever-changing environments. Regulation through the RNA transcript itself offers a faster and more cost-effective way to adapt than protein-based mechanisms and can be leveraged for diagnostic or antimicrobial purposes. However, RNA can fold into numerous intricate, not always functional structures that both expand and obscure the plethora of roles that regulatory RNAs serve within the cell. Here, we review the current knowledge of bacterial non-coding RNAs in relation to their folding pathways and interactions. We posit that co-transcriptional folding of these transcripts ultimately dictates their downstream functions. Elucidating the spatiotemporal folding of non-coding RNAs during transcription therefore provides invaluable insights into bacterial pathogeneses and predictive disease diagnostics. Finally, we discuss the implications of co-transcriptional folding and applications of RNAs for therapeutics and drug targets.

INTRODUCTION

In order to survive and thrive, bacteria must constantly tune their metabolism and overall gene expression to adjust to their ever-changing environment and ecological niches. Because of the competition between species, it is crucial for their survival that bacteria adapt quickly to transient nutritional resources as well as external threats such as antibiotics and toxins.¹


In all living organisms, gene expression starts with the synthesis of RNA molecules from the genomic DNA through the process of transcription, ultimately giving rise to the biosynthesis of proteins through translation by the ribosomes.² In bacteria, a single multi-subunit RNA polymerase (RNAP) enzyme is responsible for the synthesis of all RNA transcripts within the cell.³ The core enzyme forms a conserved architecture⁴ comprising all of the regulatory functions necessary for the efficient and accurate synthesis and folding of the transcripts during all phases of transcription, namely initiation, elongation, and termination. RNAP is subject to multiple types of regulatory processes that, in combination, determine the overall levels of expression of all genes.^{5,6}

RNA-mediated regulation of gene expression is a vital element in all living organisms, including bacteria. It plays a significant role in a variety of biological processes such as cell division,⁷ virulence,^{8,9} adaptation to environmental changes, and stress responses,^{10–12} among others. The different RNAs involved in regulation include both coding RNAs (i.e., that are translated into proteins) and non-coding RNAs (ncRNAs) that are not translated but still play key functional roles within the cell. These latter regulatory ncRNAs have been discovered to play pivotal roles in gene expression and function in all organ-

isms, contributing directly to bacterial fitness and pathogenicity.

Studies of ncRNAs in bacteria have revealed fascinating levels of complexity, both in transcriptional and post-transcriptional processes (Figure 1). A central feature of these regulatory functions is their precise timing and coordination of molecular events. Regulation often involves distinct structures that a single-stranded RNA can readily adopt based on its unique folding free energy landscape with many alternative folds,¹³ the 5' to 3' directional folding process itself that may favor specific subsets of these structures and, ultimately, the RNA's engagement with cellular processes such as target binding and regulation by other macromolecular complexes. Particularly intriguing is the phenomenon of co-transcriptional folding—the folding of an RNA transcript as it is being transcribed, possible due to its relatively high speed (microseconds for entire stem-loops) compared to the slower (tens of milliseconds per nucleotide) timescale of transcription—which plays significant roles in shaping the function of ncRNA molecules (Figure 2).¹⁴ Maintaining a temporal balance between transcription progress, folding, and RNA functional action is key to the survival of bacteria. Slight changes in the timing of transcription (too fast or too slow) therefore can have deleterious effects, leading to competitive disadvantages or even loss of viability. Examining the importance of the relative timescales of transcription and RNA folding therefore will allow for a deeper and more nuanced understanding of critical biomolecular processes. Beyond the fundamentals, advances in our understanding of the underlying timing mechanisms¹⁵ and their downstream implications might unlock transformative improvements in the design and delivery of antibiotics for bacterial disease treatment.



**Figure 1. Types of RNA-mediated regulation through ncRNAs**

Cis-encoded ncRNA elements are located in the 5'-untranslated region (5'-UTR) of mRNAs. RNA thermosensors change secondary structure through the effect of temperature, which affects the translation of mRNAs. Riboswitches are structural elements that change conformation upon binding a specific metabolite or ion (termed ligand), which in turn allows for the modulation of gene expression at the level of mRNA transcription (transcriptional riboswitch) or translation initiation (translational riboswitch). *Cis*-encoded antisense RNAs base-pair with the target mRNA and can induce degradation by ribonucleases (RNases). *Trans*-encoded ncRNAs usually interact by imperfect base-pairing with the target mRNA, often aided by RNA chaperone proteins like Hfq, ProQ, or CsrA. This interaction can either result in altered mRNA stability, through RNase degradation, or translation efficiency, by altering the accessibility of the ribosome binding site (RBS). P_S = sense promoter; P_{AS} = antisense promoter.

In this review, we aim to focus on the role and importance of ncRNAs in bacteria, the co-transcriptional folding process, and the particular significance of the relative timing of these

events. We cast a spotlight on potential links with disease and therapeutic applications and lay out future directions for research in this promising area of study.




Figure 2. Dynamic ensembles and free energy landscape define the timescale for ncRNA function

Left panel: Representative RNA free energy landscape of an RNA hairpin. The different conformations include a co-axially stacked conformation (top), a folded flexible conformation (middle), and different alternative structures (bottom). The relative energy stability of each conformation is represented by the depth of the associated free energy minimum (black line). Right panel: Time-chart of dynamic processes in RNA.

ncRNAs: MAESTROS OF BACTERIAL GENE REGULATION AND INFECTION

ncRNAs have emerged as significant players in gene regulation in all domains of life, including bacteria. Unlike coding RNAs, which are translated into proteins, ncRNAs are not recruiting the ribosome for translation, but instead typically perform regulatory functions at the transcriptional or post-transcriptional level (Figure 1). There are diverse classes of ncRNAs, varying in length and structure, with roles encompassing regulation of basal gene expression, stress responses, bacterial virulence, and adaptation to environmental changes.

Based on their sizes, two broad types of ncRNAs are distinguished: small ncRNAs, defined as less than 200 nucleotides in length, and long ncRNAs (lncRNAs) greater than 200 nucleotides. Small ncRNAs in bacteria are typically involved in the direct regulation of gene expression. Commonly, but not exclusively, they act through base-pairing with one or multiple target mRNAs to influence their stability or translation, allowing a fast and efficient gene expression response to environmental changes. Examples of these include small RNAs (sRNAs), acting in *trans*, and *cis*-regulatory elements such as riboswitches and thermosensors, which respond to cellular and/or environmental cues to modulate gene expression through their intrinsic structural changes (Figure 1).¹⁶ In addition, while they are not translated into protein, some ncRNAs contain short open reading frames (leader peptides) that recruit the ribosome and thereby participate in gene regulation.¹⁷ Conversely, transcription attenuation is a regulatory mechanism used by bacteria to regulate the production of proteins.¹⁸ It operates during the transcription process and involves premature termination of the synthesis of the mRNA transcript. This attenuation mechanism often uses a leader

sequence in the mRNA that forms a particular secondary structure acting as a premature stop signal. Like riboswitches, this is a critical process allowing bacteria to adapt and respond to their environment by controlling gene expression levels.

In contrast, lncRNAs contain more complex structural features establishing local to long-range interactions crucial for maintaining their regulatory functions in stability, organization, and functionality of the bacterial genome.^{19,20} However, in the case of bacterial lncRNAs, the current knowledge is restricted to a handful of studies that investigated the functional roles of such long transcripts during pathogen challenge or stimulation with pathogen-associated molecular patterns with their hosts.^{21,22} While the functions of bacterial lncRNAs may be confined to specific biological pathways, the molecular mode of action and potential accessory partners by which the function is mediated generally remains to be explored.

Bacterial small ncRNAs operate at all levels of gene regulation including transcription, translation, mRNA stability, and foreign gene silencing, requiring them to use various mechanisms to execute their regulatory functions (Figure 1). In *Escherichia coli* (*E. coli*), about 200 distinct *trans*-acting sRNAs 50–500 nucleotides in length are found in genomic locations distinct from their targets.²³ They typically share partial complementarity with their target mRNAs and potentially establish base-pairing to or near the target Shine-Dalgarno (SD) sequence (usually 10–25 base pairs long) to prevent ribosome binding, thus inhibiting translation initiation and/or activating RNA degradation.^{24,25} In many cases, due to their limited complementarity as well as the competing secondary structures of both regulator and target, *trans*-encoded sRNAs engage their target with the help of chaperone proteins such as Hfq^{26,27} or ProQ^{28–30} to promote hybridization and sRNA-mediated regulation (Figure 1).

Cis-acting ncRNAs, in contrast, are encoded in the same DNA region as their putative target, usually embedded in the 5' untranslated region of the corresponding target gene. They are often highly structured RNA motifs such as riboswitches and RNA thermometers that remodel their downstream expression platforms in response to the upstream aptamer domains engaging external (*trans*-acting) cues that include cellular metabolite and ion levels, and/or temperature, and modulate translation initiation,³¹ transcription termination,^{32,33} or mRNA

stability (Figure 1).^{34,35} So far, ~55 riboswitch classes of known function have been discovered through sequence and structure conservation, combined with mechanistic studies, and perhaps many more are still expected to be found in niche or difficult-to-culture bacterial species.³⁶

In addition to the regulation of gene expression through base-pairing with their target mRNAs, ncRNAs have evolved and adapted to also interact with a variety of regulatory proteins.^{37–39} For example, ncRNAs can modulate their activity by mimicking and thus efficiently competing with their cognate targets. One intriguing instance is the Csr/Rsm regulatory network, a global carbon storage regulator common in pathogenic bacteria. In this two-component system, sRNAs can directly bind the carbon storage regulator A protein to sequester it from interacting with its cognate mRNA target.^{40–42} This can result in the activation of the translation of previously blocked transcripts.

The diverse roles of ncRNAs in bacterial disease make them attractive intervention targets

Since ncRNAs play important roles in bacterial physiology, their ubiquitous nature and variety of functions, particularly in regulatory processes, make them significant contributors to bacterial adaptability and infection virulence. Additionally, the dysregulation of ncRNAs, such as alterations in their expression through mutations, can lead to bacterial infection and disease.

One notable example is the ncRNA molecule RNAIII in *Staphylococcus aureus* (*S. aureus*), often associated with various human and animal diseases ranging from minor skin infections to severe diseases such as pneumonia and meningitis.⁴³ RNAIII is the key effector of the *agr* quorum-sensing system and controls the expression of numerous virulence factors through a sophisticated network of regulatory proteins and RNAs.^{44,45} Interestingly, a prophage-induced sRNA, *sprY*, has been discovered to form a complex with RNAIII *in vivo*, decreasing hemolytic and virulence activity of *S. aureus*.⁴⁶ Another example is the sRNA *gcvB* identified in *E. coli* and *Salmonella enterica* (*S. enterica*), which indirectly impacts pathogenicity.⁴⁷ *GcvB* regulates the transport and assimilation of amino acids, which in turn could be related to virulence gene expression.^{48–50} Thus, despite not being always directly involved in virulence, ncRNAs can significantly impact bacterial pathogenicity and the progression of disease through regulatory networks that act at multiple levels during the bacterial life cycle.⁵¹

Recently PinT, an sRNA found in *S. enterica* activated by PhoP within the infected host, was found to control the timing of the expression of invasion-related effectors and virulence genes, causing changes in both coding and non-coding host transcripts.^{52,53} The bacterial pathogen *Salmonella* uses a type 3 secretion system to infect intestinal cells, but ceases expressing this system upon intracellular survival. Research supports that PinT plays a significant role in transitioning *Salmonella* from invasion to intracellular survival based on regulation of its virulence genes by the PhoPQ system.

Given their critical roles in regulating bacterial pathogenicity and the specific association that certain ncRNAs have with diseases, these molecules offer promising potential as disease biomarkers. That is, they can be used in the identification of bacterial strains or specific virulence states, paving the way for personalized treatment strategies. For instance, by

measuring the expression level of a particular ncRNA in a patient, it may be possible to detect the presence of a specific bacterial infection or even predict its severity. The fact that ncRNA levels can rapidly change in response to environmental or metabolic shifts^{54,55} makes them particularly attractive as real-time disease reporters. In a recent study, an sRNA encoded by the gene *sicX* was discovered to be strongly induced in *Pseudomonas aeruginosa* (*P. aeruginosa*) by low-oxygen conditions, in turn post-transcriptionally regulating anaerobic ubiquinone biosynthesis.⁹ Upon deletion of this gene, the authors found that *P. aeruginosa* switches from a chronic to an acute life cycle in multiple mammalian models of infection. Therefore, expression and abundance of this sRNA constitute one new biomarker for bacterial infection and could be exploited diagnostically.


A better understanding of the molecular mechanisms of ncRNA involvement in disease can lead to the development of novel therapeutic strategies. For instance, molecules that inhibit the action of disease-related ncRNAs or essential genes regulated by ncRNAs could provide a new class of antibiotic compounds to combat bacterial infections. This notion is exemplified in the context of riboswitches since they bind a specific ligand and generally control the expression of essential genes specific to a bacterial species. For instance, analogs of the natural ligand with antibiotic properties were found targeting the guanine,^{56–58} flavine mononucleotide (FMN),^{59,60} and thiamine pyrophosphate⁶¹ riboswitches. Conversely, anti-sense oligonucleotides targeting riboswitches found in pathogens such as *Listeria monocytogenes* or *S. aureus* have also been successfully deployed,^{62,63} expanding our arsenal to fight the ever-expanding occurrence of antibiotic-resistant strains.⁶⁴

To fully realize these prospects, comprehensive catalogs of ncRNAs and their regulatory networks in bacterial pathogens will need to be established.^{65,66} Furthermore, the development of technologies for the sensitive detection of ncRNAs in clinical samples will be instrumental. The complex choreography of ncRNA expression, encompassing spatial and temporal controls, heralds an exciting frontier in understanding and combating bacterial diseases.

Utilizing ncRNAs themselves as promising therapeutics

Recent years have seen significant strides in harnessing the power of ncRNAs for bacterial disease treatment.^{67,68} Apart from a diagnostic target, novel therapeutic technologies—such as those utilizing widespread bacterial CRISPR-Cas defense systems against bacteriophages—are capitalizing on the regulatory capabilities of ncRNAs.⁶⁹ In particular, CRISPR-Cas9, guided by specific ncRNA sequences, can be directed to target and edit bacterial genomes. In an elegant example, this technology has been harnessed to develop “anti-virulence” therapies that disarm pathogens without killing them, aiming to minimize the evolutionary pressure for resistance development.⁷⁰ Another advancement has been the use of RNA interference technology in bacteria, wherein short ncRNA molecules are designed to inhibit the expression of specific genes by base-pairing with their cognate mRNAs and preventing their translation.⁷¹

Despite these practical examples and the constant increase in our understanding of ncRNA-mediated regulatory pathways



(legend on next page)

in bacteria, further work is needed to be able to surgically target specific pathogenic species rather than killing a patient's entire microbiome with broad-spectrum antibiotics. RNA-based therapeutics lend themselves to more focused targeting due to their heightened information content relative to small-molecule drugs with more limited chemical features. A better understanding of ncRNA mechanisms and functions *in vivo*, and especially during bacterial infection, is critical for the development of new strategies and tools against the constantly increasing risk of a new epidemic of antibiotic-resistant bacterial strains.^{64,72}

ncRNAs FOLD CO-TRANSCRIPTIONALLY INTO INTRICATE STRUCTURES ON A RUGGED ENERGY LANDSCAPE

Whereas a plethora of ncRNAs such as sRNAs are thought to modulate gene expression at the post-transcriptional level, increasing evidence points toward a more complex regulation that operates during the transcription process itself. RNA molecules in general, and ncRNAs such as riboswitches in particular, are complex structures folded into unique three-dimensional shapes.^{73,74} The intricate architecture of RNA molecules, ranging from simple base-pairing to forming binding pockets highly specific for cations or complex metabolites, is crucial for their function.^{75–78} In addition, all RNA molecules undergo structural transitions that are either stabilized or destabilized under particular conditions with, in most cases, the alternative structures coexisting in the cell, at times at thermodynamic equilibrium (Figure 2).⁷⁹ Therefore, RNA structure can be described as a distribution of various conformations dictated by the nucleotide sequence (Figure 2). The many possible conformers and intermediate structures have their individual free energies and form an ensemble on a rugged (bumpy) free energy landscape.¹³ Since thermodynamic stability (or low free energy) is favored, the proportion of each population is unequal, with some conformations more abundant than others in the ensemble. Almost isoenergetic sub-ensembles then give rise to multiple energy minima, most of which represent suboptimal structures within the landscape (Figure 2). Since the overall majority of conformations, however, exhibit higher (less favorable) free energies, the RNA landscape is dominated by only relatively few low-energy conformations, with the rest representing relatively unstable intermediates and outliers (sometimes referred to as "excited" states, even though they are still in thermal equilibrium).⁸⁰ Transition rates between these conformations depend on the height of the separating energetic barriers. With their much more favorable secondary structure energetics than proteins, the unproductive local energy minima of RNA molecules tend to produce kinetic traps. In some instances, this behavior manifests as very long-lived heterogeneities because of topological or other folding constraints (Figure 2).^{81,82}

Co-transcriptional folding as the key to unraveling RNA-mediated regulation

Work from the early 1980s established that RNA transcripts in the cell fold into secondary structures as they are being transcribed by RNAP,⁸³ rather than adopting their final structure upon transcription completion. Such a dynamic process termed co-transcriptional folding directly affects the available energy barriers of folding with the potential to kinetically trap fast folding, but energetically less favorable states in local energetic minima.^{76,84,85}

Since transcription occurs sequentially from the 5' to the 3' end of the RNA chain,⁸⁶ newly synthesized RNA segments can start to fold before the downstream end of the transcript is available. As a result, co-transcriptional folding is linked intimately to the direction of the transcription process, which promotes dynamic, local, close-proximity interactions of the nascent RNA. Additionally, the rate of transcription, or the RNAP's velocity, directly affects RNA folding.^{87–89} Indeed, while the transcription rate average ranges from 20 to 80 nucleotides per second, depending on the growth conditions of a given bacterial species,⁹⁰ local RNA secondary structure folds much faster, on a microsecond timescale, in turn raising opportunities for kinetically trapping conformations that then may take milliseconds to minutes or even hours to further evolve (Figure 2). In this context, transcriptional pausing,^{5,91} or the temporary off-state of the RNAP during transcription, has been implicated as critical to the folding of RNA structures (Figure 3). Transcriptional pausing is a ubiquitous mechanism found in all domains of life that dictates vastly varying local speeds of the RNAP with profound impact on gene expression.⁹¹ In eukaryotes, transcriptional pausing and co-transcriptional events have been found to influence RNA processing, such as mRNA splicing.^{92–97} In bacteria, the interaction of the RNA transcript with RNAP and/or accessory proteins such as transcription factors can induce transcriptional pausing and modulate numerous biological processes, including transcription termination^{98,99} protein recruitment,^{100–102} RNA folding,^{103,104} transcription-coupled DNA reparation,^{105–107} and transcription-translation coupling.^{108–110} The latter coupling is unique to bacterial species with their single cellular compartment.

For ncRNAs, which often perform functions based on their intricate structures, the process of co-transcriptional folding has recently been under intense study since it influences the final shape of the RNA transcript. Pioneering work on the catalytic *Tetrahymena* group I intron¹¹¹ and ribonuclease P¹¹² revealed that the enzymatic activity of denatured, then renatured synthetic RNAs is dramatically different from that obtained using nascent transcripts, consistent with the notion that the kinetics of transcription elongation are important for the ordered folding of nascent transcripts. Another example of this behavior is the FMN-sensing riboswitch from *Bacillus subtilis* (*B. subtilis*) that, upon ligand binding, regulates transcription elongation through

Figure 3. RNA polymerase (RNAP) pausing as a fulcrum for cellular processes dictated by ncRNAs

- (A) Example of a pausing delay during transcription elongation that allows efficient ligand binding to a riboswitch, triggering RNA folding into a specific conformation.
- (B) Transcriptional pausing is a mandatory step for efficient intrinsic transcription termination, favoring terminator hairpin folding.
- (C) RNAP pausing in the vicinity of the ribosome-binding site/start codon allows proper coupling between the transcription and translation machineries in bacteria.

the formation of a terminator stem.^{113–115} In this example, metabolite binding and stabilization of an alternative RNA conformation occur within key positions defined by RNAP pausing, further highlighting the critical importance of co-transcriptional processes for ncRNA function.

Biology along timescales: The interplay of transcription and folding kinetics

One of the most fascinating aspects of ncRNA function is that it is deeply intertwined with RNA structure, which in turn is ultimately dependent on the transcription process. This involves the RNA molecule folding into its functional shape while still being transcribed, often with the 5' and 3' ends pairing at the very end of transcription,¹¹⁶ perhaps to signal finality through topological closure. Notably, the entire transcription/folding process is dynamic, adaptable, and extends over a range of timescales that adjudicate the final ncRNA structure (Figure 2).¹⁴ Understanding the kinetics of transcription relative to those of secondary and tertiary structure folding events thus becomes crucial for understanding ncRNA function. Consequently, co-transcriptional ncRNA folding is not just about space, but also about time. Nature exploits this inherent transcription-folding coupling, and characterizing the associated sequence of events in detail stands to open new avenues for the treatment of bacterial diseases.

The varying speed with which transcription proceeds affects the sequence in which sequential RNA regions emerge from the RNAP exit channel and start to interact, influencing the folding pathway. In general, slower transcription rates may provide more opportunity for regions transcribed early to fold onto themselves, with the potential to lead to alternative conformations compared to a renatured, thermodynamically more stable structure.^{117–120} In contrast, faster transcription rates may give distal base-pairing interactions an opportunity to form, potentially driving the formation of a different structure (Figure 3A).^{87,121} Therefore, the relative rate constants of RNAP progress during transcription and of RNA folding play a pivotal role in determining the final RNA structure and its ability to trigger downstream biological processes at a timescale suitable for the cell (Figure 2). For instance, in bacteria, intrinsic transcription termination depends on the formation of a longer terminator helix versus competing shorter anti-terminator helix and is intimately linked to transcriptional pausing (Figure 3B).^{6,122,123} In this essential process, co-transcriptional folding—which itself is influenced by parameters such as temperature, ionic conditions, and cofactors—and the rate of transcription together dictate whether the RNAP is allowed to continue, thus integrating environmental cues into the regulatory outcome.

Coordinating structure and function through kinetic competition

In addition to determining their structure and function, co-transcriptional folding enables nascent RNA transcripts to interact *in situ* with other cellular components (i.e., proteins, other RNAs, metabolites, ions) at the right time and place, empowering them with adaptability to cellular conditions. In fact, the spatio-temporal coordination of transcription, translation, and RNA degradation also have an important role in shaping the functionality of ncRNA structures in fine-tuning gene expression regula-

tion. Many biological processes are tightly coupled, and the harmonized timing of these processes can lead to allosteric effects. Practical examples of such tightly coordinated processes among regulatory pathways include the time windows allowed for the ligand sensing by riboswitches,^{115,124,125} recruitment of transcription factors,^{100,126,127} stepwise assembly of proteins with ribosomal RNA during ribosome biogenesis,^{128–131} and sRNA loading onto their mRNA targets.¹³²

One notable example is the coupling between transcription and translation, which is unique to bacterial species because of their lack of subcellular compartmentalization. Transcription-translation coupling is defined by the translation of an mRNA into protein concomitantly with its synthesis by RNAP (Figure 3C). During this process, the pioneering ribosome closely follows and physically interacts with the downstream RNAP, spatiotemporally coupling the two processes through a mega complex termed the “expressome.”^{133–136} Through the resulting concomitant mRNA transcription and translation, the RNA transcript is protected by the ribosome from degradation by cellular ribonucleases²⁵ or premature transcription termination mediated by the ATP-dependent helicase termed Rho factor (Figure 1).^{137,138} Alterations in the coupling of these processes can result in global changes in the cellular protein levels and modulate cellular responses to environmental stimuli (Figure 3C). Recently, single-molecule studies have unveiled an intriguing mechanism in which co-transcriptional folding of a riboswitch uncouples transcription and translation as a function of ligand binding.¹⁰⁸ In this study, surveying the transcription rate during transcription-translation coupling revealed that ligand binding to the preQ₁-sensing riboswitch from *B. anthracis* triggers a conformational change that leads to ribosome stalling in the translation initiation region, in turn holding the RNAP in place at a specific pause site and preventing downstream RNA transcription. While the molecular and structural details of this ncRNA-based regulatory mechanism remain unknown, its existence underscores the profound impact that small, but highly structured and ligand-responsive ncRNAs can have on the macromolecular complexes of gene expression.^{139,140}

Another instance is the folding pathway of the fluoride-sensing riboswitch that integrates multiple signals to modulate gene expression.^{100,141} Research on the transcriptional *crcB* fluoride riboswitch from *Bacillus cereus* revealed three interchanging conformations throughout the transcription process. A single fluoride anion locks the magnesium-induced state, governed by a single long-range, nesting base pair. Additionally, RNAP influences the free energy landscape, promoting riboswitch docking. Fluoride binding is an early step in folding the transcript into the docked conformation, a mechanism that leads to cellular fluoride detoxification. Ligand and transcription factor NusA both bind the co-transcriptionally folded RNA, affecting the process of downstream RNAP pausing and termination of transcription. The transcription factor binds reversibly, assessing the complex for co-transcriptionally folded RNA duplexes and altering the transcription rate based on the riboswitch's structure. This dynamic regulation is likely to allow for quick adaptive bacterial transcription.

Nature makes ubiquitous use of these features of RNA folding. Another example is the recent identification of the “anti-P1” intermediate present among translational riboswitches in




Figure 4. The folding mechanism underlying the exemplary gene regulation by the *E. coli thiC* riboswitch

In the absence of TPP (left), the riboswitch remains competent for efficient co-transcriptional ligand binding until the RNAP reaches the regulatory checkpoint pause site in the vicinity of the start codon. At this pause site, the energetically favored anti-P1 prevents folding of the riboswitch into the TPP-bound state and the

(legend continued on next page)

E. coli.^{117,124} Upon ligand binding, this regulatory switch induces the formation of an energetically favored sequestering stem in the expression platform that prevents ribosome access to the SD sequence. This conformational trap can be resolved prior to the regulatory decision by additional factors in the system, in this case by forming an alternative structure termed anti-P1 that instead holds the ribosome binding site “open” (Figure 4). Interestingly, this specific RNA structure that formed co-transcriptionally is central for regulation of gene expression at multiple levels. Indeed, while “holding” the aptamer in the ligand-free conformation, it also prevents spurious regulation by the Rho termination factor by sequestering its potential binding site on the mRNA (Figure 4).¹²⁴ Such induction of structural rearrangements by external factors or local RNA motifs that promote structural transitions is a primary mechanism employed by ncRNAs and particularly structured RNAs such as riboswitches.

At its most basic, the relative kinetics of ncRNA folding, ligand-induced conformational changes, transcription elongation and pausing, and translation initiation determine the fractional partitioning into distinct gene regulatory outcomes. Therefore, a thorough understanding of ncRNA function requires not only appreciating static structures but also—to equal measure—the dynamic features that are coordinated in time to lead to the desired spatiotemporal control of gene expression and thus capacity for cellular adaptation. Time-resolved probing¹⁵ and the ensuing understanding of the temporal dimension of ncRNA biology will add further critical layers to the study of ncRNAs and possibly offer opportunities for versatile therapeutic strategies against bacterial pathogens.

The impact of co-transcriptional folding on bacterial disease pathologies

Overall, bacterial ncRNAs display a remarkable complexity and sophistication, empowering flexible gene regulation. Their diverse roles and the precise timing of the regulatory events they affect enable their broad impact on bacterial fitness and virulence.

The importance of co-transcriptional folding extends beyond the folding of functional ncRNAs; it also plays a vital role in disease pathology. When the process of co-transcriptional folding does not proceed correctly due to cellular stress, it can lead to the production of misfolded RNAs that can lead to loss of function or even gain of undesired function and thereby harm the cellular machinery, leading to loss of cell viability. A classic example is observed in several human neurodegenerative diseases, where incorrect RNA folding can result in the formation of toxic aggregates.^{142–144} Intriguingly, cohabiting bacteria can compete with one another by secreting and uptaking ncRNA fragments that act as growth suppressors in an apparent tug-of-war.¹⁴⁵ Moreover, single nucleotide polymorphisms can lead to dysregulation of co-transcriptional folding. For example, variants of RNA thermosensors were found by whole genome sequencing of the pathogenic bacterium *Neisseria meningitidis*,

which causes invasive meningococcal disease such as septicemia and/or meningitis if it can enter the host bloodstream. Bacterial isolates that harbor such variants are characterized by a hypercapsulation phenotype and are dominant during invasive disease compared to the carrier state.¹⁴⁶ While the latter example is recent, it links ncRNA mutations to bacterial disease progression, possibly heralding similar discoveries for other pathogens.⁹

Analogous to mutations found in microRNAs and fragments of tRNAs that can lead to human cancer,^{147–151} alterations of bacterial ncRNA sequences might change RNA folding kinetics, expression level, and/or functionality such as in target identification by an sRNA. Additionally, environmental factors such as a change in temperature, pH,¹⁵² or ion availability^{153,154} can also lead to alterations in the co-transcriptional folding process, underscoring the nuanced balance required for maintaining RNA functionality. In at least one case, it has been observed that ncRNAs can compensate for changes in, e.g., temperature by exploiting compensatory structural elements that dampen the effects of environmental changes for more robust riboswitching.¹⁵⁵

On the therapeutic front, a better understanding of co-transcriptional folding paves the way toward developing unprecedented RNA-targeted therapies. Strategies aimed at correcting misfolded RNAs or employing small molecules that can stabilize the correctly folded RNAs are gaining momentum.^{64,156,157} Intervention at the co-transcriptional level could allow for modulating bacterial gene expression with high specificity, highlighting the therapeutic potential of targeting co-transcriptional folding and related processes with antibacterial compounds. Future studies to probe the detailed mechanisms regulating co-transcriptional folding, the factors influencing it, and their roles in physiology and disease will be crucial toward addressing the ever-increasing threat of bacterial diseases.

FUTURE PERSPECTIVES AND CONCLUSIONS

Despite the remarkable potential and recent advancements in our understanding ncRNA-based gene regulation and the underlying, finely balanced temporal coordination of events, several challenges persist. First, still more tools are needed to fully dissect the broad timescales of processes involved—ranging from microseconds to minutes—and understand their competition and harmonization. Second, in order to utilize these insights to derive fresh antibacterial strategies based on intervening ncRNAs that promise higher species specificity, more delivery methods will have to be developed to reliably transfer RNA molecules into bacterial cells, which tend to have robust protection mechanisms against such intrusions.^{158–160} Third, for therapeutics applications, the inherently transient stability of RNA, susceptibility to targeted degradation, and the potential for off-target effects are significant concerns. Future research must address all of these challenges, develop more targeted delivery

direct termination of transcription by Rho factor, instead ultimately leading to transcription-translation coupling and protein synthesis. In the presence of TPP (right), folding of the riboswitch in the TPP-bound state leads to two gene regulatory responses. Transcription termination mediated by Rho factor occurs at the long-lived regulatory pause site near the start codon. Complexes that fail to terminate and instead carry on transcription into the coding region allow the formation of the sequestering stem, inhibiting translation initiation. In the downstream coding region, absence of translation can lead to RNA degradation by ribonucleases or transcription termination by Rho (polarity). Adapted from Ref.¹²⁴

methods,^{161,162} enhance the stability of RNA therapeutics,^{163,164} and improve our understanding of potential side effects.

Advances in bioinformatics and artificial intelligence^{165–168} as well as experimental techniques are expected to uncover still more ncRNAs, help characterize their functional roles and mechanisms, and aid in predicting the effects of their manipulation.¹⁶⁹ Recent improvements in structure prediction based on artificial intelligence have significantly improved our modern toolkits to address this question. Protein structure prediction problems have been solved for many proteins thanks to the recent advent of AlphaFold,^{170,171} promising the discovery of new antibiotic targets. However, due to the limited number of RNA structures available and their insufficient quality, these deep learning methods are still challenging to apply to 3D RNA structures.¹⁷² Here, the constant improvement of *in vivo* and *in vitro* structural probing methods^{173–180} in terms of temporal and spatial resolution is expected to help build a comprehensive framework that integrates biological, computational, and clinical research, which will be crucial for a successful development of robust ncRNA-based, bacterium-specific, therapeutics. Recent advances in RNA structural probing methods such as selective 2'hydroxyl acetylation followed by primer extension or dimethyl sulfate-probing have the potential to further advance this goal. Indeed, through a combination with deep sequencing and computational analysis, these methods have unveiled unique RNA conformers among the vast population of transcripts probed.¹⁷⁷ More specifically, DANCE-MaP (deconvolution and annotation of ribonucleic conformational ensembles) presents an innovative tool for understanding gene regulation, specifically through its ability to elucidate the structural dynamics of RNAs like 7SK. As a global regulator of gene transcription, 7SK ncRNA sequesters the transcription factor P-TEFb. This function necessitates intricate shifts in RNA structure that, given their complexity, present a significant challenge for characterization. DANCE-MaP helps overcome this challenge by providing detailed views of these structural perturbations. In particular, DANCE-MaP enables the definition of per-nucleotide reactivity, direct base-pairing interactions, tertiary interactions, and thermodynamic populations for each state within an RNA structural ensemble. This technological advance has led to the discovery of a substantial structural switch within 7SK RNA, linking the dissolution of the P-TEFb-binding site to remodeling activity at distant release factor binding sites. The structural balance within 7SK RNA changes in response to cell growth and stress, providing the potential for targeted intervention to alter the expression of P-TEFb-responsive genes. By revealing the precise dynamics of 7SK RNA, DANCE-MaP offers support for how RNA structural dynamics can serve an integrating function for a variety of cellular signals controlling transcription. The power of DANCE-MaP lies in its potential to define RNA dynamics within the cellular context as a key to better understanding the mechanisms of gene regulation.

Time-resolved cryoelectron microscopy (cryo-EM) is another robust tool in the realm of structural biology that can be used synergistically with single-molecule level RNA dynamics data to enhance our insight into bacterial biology and antibiotic design. Cryo-EM visualizes macromolecular assemblies and even entire cells at high resolution and in a near-native state, capturing the structural dynamics of protein and nucleic acid

assemblies. Whereas techniques like DANCE-MaP can reveal intricate details of RNA folding and interactions, cryo-EM can contextualize these interactions within larger molecular assemblies. The time-resolved aspect of this technique allows for the observation of conformational changes over time, offering a lens for viewing the dynamism of macrostructures.

In the context of antibiotic design, the integration of time-resolved cryo-EM and single-molecule RNA dynamics techniques can provide a more comprehensive understanding of the cellular processes that can serve as potential drug targets. For example, time-resolved cryo-EM can provide a view of the overall structure and motion of the bacterial ribosome,¹⁷⁹ a primary target of many antibiotics, while DANCE-MaP can delve into the details of RNA and small-molecule interactions with the ribosome, and how these features affect the function of the ribosome. In the fight against bacterial resistance, the resulting more detailed and nuanced understanding of bacterial biology attained by combining the above techniques inevitably will lead to new strategies for antibiotic design. The targeting of the precise locations and processes most essential for bacterial function, and therefore less prone to evolve resistance, will ultimately contribute to the preservation of human health.

An essential foundation in these endeavors will be the continued expansion of our understanding of co-transcriptional folding and the all-important time dimension that governs it.¹⁴

ACKNOWLEDGMENTS

This work was supported by NIH grant R35 GM131922 and NSF grant MCB 2140320 to N.G.W.

AUTHOR CONTRIBUTIONS

A.C. and N.G.W. conceived and wrote the manuscript; A.C. created the figures.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

- Bakkeren, E., Diard, M., and Hardt, W.-D. (2020). Evolutionary causes and consequences of bacterial antibiotic persistence. *Nat. Rev. Microbiol.* 18, 479–490.
- Crick, F. (1970). Central dogma of molecular biology. *Nature* 227, 561–563.
- Lane, W.J., and Darst, S.A. (2010). Molecular evolution of multisubunit RNA polymerases: structural analysis. *J. Mol. Biol.* 395, 686–704.
- Werner, F., and Grohmann, D. (2011). Evolution of multisubunit RNA polymerases in the three domains of life. *Nat. Rev. Microbiol.* 9, 85–98.
- Zhang, J., and Landick, R. (2016). A Two-Way Street: Regulatory Interplay between RNA Polymerase and Nascent RNA Structure. *Trends Biochem. Sci.* 41, 293–310.
- Ray-Soni, A., Bellecourt, M.J., and Landick, R. (2016). Mechanisms of Bacterial Transcription Termination: All Good Things Must End. *Annu. Rev. Biochem.* 85, 319–347.
- Grützner, J., Remes, B., Eisenhardt, K.M.H., Scheller, D., Kretz, J., Maduguri, R., McIntosh, M., and Klug, G. (2021). sRNA-mediated RNA processing regulates bacterial cell division. *Nucleic Acids Res.* 49, 7035–7052.

8. Diallo, I., and Provost, P. (2020). RNA-Sequencing Analyses of Small Bacterial RNAs and their Emergence as Virulence Factors in Host-Pathogen Interactions. *Int. J. Mol. Sci.* **21**, 1627.
9. Cao, P., Fleming, D., Moustafa, D.A., Dolan, S.K., Szymanik, K.H., Redman, W.K., Ramos, A., Diggle, F.L., Sullivan, C.S., Goldberg, J.B., et al. (2023). A *Pseudomonas aeruginosa* small RNA regulates chronic and acute infection. *Nature* **618**, 358–364.
10. Pernitzsch, S.R., Alzheimer, M., Bremer, B.U., Robbe-Saule, M., De Reuse, H., and Sharma, C.M. (2021). Small RNA mediated gradual control of lipopolysaccharide biosynthesis affects antibiotic resistance in *Helicobacter pylori*. *Nat. Commun.* **12**, 4433.
11. Feugeas, J.-P., Tourret, J., Launay, A., Bouvet, O., Hoede, C., Denamur, E., and Tenaillon, O. (2016). Links between Transcription, Environmental Adaptation and Gene Variability in *Escherichia coli*: Correlations between Gene Expression and Gene Variability Reflect Growth Efficiencies. *Mol. Biol. Evol.* **33**, 2515–2529.
12. Zhang, Y., Burkhardt, D.H., Rouskin, S., Li, G.-W., Weissman, J.S., and Gross, C.A. (2018). A Stress Response that Monitors and Regulates mRNA Structure Is Central to Cold Shock Adaptation. *Mol. Cell* **70**, 274–286.e7.
13. Marek, M.S., Johnson-Buck, A., and Walter, N.G. (2011). The shape-shifting quasispecies of RNA: one sequence, many functional folds. *Phys. Chem. Chem. Phys.* **13**, 11524–11537.
14. Al-Hashimi, H.M., and Walter, N.G. (2008). RNA dynamics: it is about time. *Curr. Opin. Struct. Biol.* **18**, 321–329.
15. Ray, S., Chauvier, A., and Walter, N.G. (2019). Kinetics coming into focus: single-molecule microscopy of riboswitch dynamics. *RNA Biol.* **16**, 1077–1085.
16. Bédard, A.S.V., Hien, E.D.M., and Lafontaine, D.A. (2020). Riboswitch regulation mechanisms: RNA, metabolites and regulatory proteins. *Biochim. Biophys. Acta. Gene Regul. Mech.* **1863**, 194501.
17. Kriner, M.A., and Groisman, E.A. (2015). The bacterial transcription termination factor Rho coordinates Mg(2+) homeostasis with translational signals. *J. Mol. Biol.* **427**, 3834–3849.
18. Turnbough, C.L. (2019). Regulation of Bacterial Gene Expression by Transcription Attenuation. *Microbiol. Mol. Biol. Rev.* **83**, e00019-19.
19. Puerta-Fernandez, E., Barrick, J.E., Roth, A., and Breaker, R.R. (2006). Identification of a large noncoding RNA in extremophilic eubacteria. *Proc. Natl. Acad. Sci. USA* **103**, 19490–19495.
20. Weinberg, Z., Perreault, J., Meyer, M.M., and Breaker, R.R. (2009). Exceptional structured noncoding RNAs revealed by bacterial metagenome analysis. *Nature* **462**, 656–659.
21. Harris, K.A., and Breaker, R.R. (2018). Large noncoding RNAs in bacteria. *Microbiol. Spectr.* **6**.
22. Shirahama, S., Miki, A., Kaburaki, T., and Akimitsu, N. (2020). Long Non-coding RNAs Involved in Pathogenic Infection. *Front. Genet.* **11**, 454.
23. Felden, B., and Augagneur, Y. (2021). Diversity and Versatility in Small RNA-Mediated Regulation in Bacterial Pathogens. *Front. Microbiol.* **12**, 719977.
24. Saramago, M., Bárria, C., Dos Santos, R.F., Silva, I.J., Pobre, V., Domíngues, S., Andrade, J.M., Viegas, S.C., and Arraiano, C.M. (2014). The role of RNases in the regulation of small RNAs. *Curr. Opin. Microbiol.* **18**, 105–115.
25. Deana, A., and Belasco, J.G. (2005). Lost in translation: the influence of ribosomes on bacterial mRNA decay. *Genes Dev.* **19**, 2526–2533.
26. Holmqvist, E., Wright, P.R., Li, L., Bischler, T., Barquist, L., Reinhardt, R., Backofen, R., and Vogel, J. (2016). Global RNA recognition patterns of post-transcriptional regulators Hfq and CsrA revealed by UV crosslinking *in vivo*. *EMBO J.* **35**, 991–1011.
27. Zhang, A., Wasserman, K.M., Rosenow, C., Tjaden, B.C., Storz, G., and Gottesman, S. (2003). Global analysis of small RNA and mRNA targets of Hfq. *Mol. Microbiol.* **50**, 1111–1124.
28. Smirnov, A., Förstner, K.U., Holmqvist, E., Otto, A., Günster, R., Becher, D., Reinhardt, R., and Vogel, J. (2016). Grad-seq guides the discovery of ProQ as a major small RNA-binding protein. *Proc. Natl. Acad. Sci. USA* **113**, 11591–11596.
29. Smirnov, A., Wang, C., Drewry, L.L., and Vogel, J. (2017). Molecular mechanism of mRNA repression in trans by a ProQ-dependent small RNA. *EMBO J.* **36**, 1029–1045.
30. Attaiech, L., Boughammoura, A., Brochier-Armanet, C., Allatif, O., Peillard-Fiorente, F., Edwards, R.A., Omar, A.R., MacMillan, A.M., Glover, M., and Charpentier, X. (2016). Silencing of natural transformation by an RNA chaperone and a multitarget small RNA. *Proc. Natl. Acad. Sci. USA* **113**, 8813–8818.
31. Sherwood, A.V., Grundy, F.J., and Henkin, T.M. (2015). T box riboswitches in Actinobacteria: Translational regulation via novel tRNA interactions. *Proc. Natl. Acad. Sci. USA* **112**, 1113–1118.
32. Hollands, K., Proshkin, S., Sklyarova, S., Epstein, V., Mironov, A., Nudler, E., and Groisman, E.A. (2012). Riboswitch control of Rho-dependent transcription termination. *Proc. Natl. Acad. Sci. USA* **109**, 5376–5381.
33. Hollands, K., Sevostyanova, A., and Groisman, E.A. (2014). Unusually long-lived pause required for regulation of a Rho-dependent transcription terminator. *Proc. Natl. Acad. Sci. USA* **111**, E1999–E2007.
34. Caron, M.-P., Bastet, L., Lussier, A., Simoneau-Roy, M., Massé, E., and Lafontaine, D.A. (2012). Dual-acting riboswitch control of translation initiation and mRNA decay. *Proc. Natl. Acad. Sci. USA* **109**, E3444–E3453.
35. Richards, J., and Belasco, J.G. (2021). Widespread Protection of RNA Cleavage Sites by a Riboswitch Aptamer that Folds as a Compact Obstacle to Scanning by RNase E. *Mol. Cell* **81**, 127–138.e4.
36. Kavita, K., and Breaker, R.R. (2023). Discovering riboswitches: the past and the future. *Trends Biochem. Sci.* **48**, 119–141.
37. Mellin, J.R., Koutero, M., Dar, D., Nahori, M.-A., Sorek, R., and Cossart, P. (2014). Riboswitches. Sequestration of a two-component response regulator by a riboswitch-regulated noncoding RNA. *Science* **345**, 940–943.
38. DebRoy, S., Gebbie, M., Ramesh, A., Goodson, J.R., Cruz, M.R., van Hoof, A., Winkler, W.C., and Garsin, D.A. (2014). Riboswitches. A riboswitch-containing sRNA controls gene expression by sequestration of a response regulator. *Science* **345**, 937–940.
39. Sedlyarova, N., Rescheneder, P., Magán, A., Popitsch, N., Rziha, N., Bilusic, I., Epstein, V., Zimmermann, B., Lybecker, M., Sedlyarov, V., et al. (2017). Natural RNA Polymerase Aptamers Regulate Transcription in *E. coli*. *Mol. Cell* **67**, 30–43.e6.
40. Sahr, T., Rusniok, C., Impens, F., Oliva, G., Sismeiro, O., Coppée, J.Y., and Buchrieser, C. (2017). The *Legionella pneumophila* genome evolved to accommodate multiple regulatory mechanisms controlled by the CsrA-system. *PLoS Genet.* **13**, e1006629.
41. Romeo, T., and Babitzke, P. (2018). Global Regulation by CsrA and Its RNA Antagonists. *Microbiol. Spectr.* **6**.
42. Figueiroa-Bossi, N., Schwartz, A., Guillemandet, B., D'Heygère, F., Bossi, L., and Boudvillain, M. (2014). RNA remodeling by bacterial global regulator CsrA promotes Rho-dependent transcription termination. *Genes Dev.* **28**, 1239–1251.
43. Tong, S.Y.C., Davis, J.S., Eichenberger, E., Holland, T.L., and Fowler, V.G. (2015). *Staphylococcus aureus* Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management. *Clin. Microbiol. Rev.* **28**, 603–661.
44. Gupta, R.K., Luong, T.T., and Lee, C.Y. (2015). RNAIII of the *Staphylococcus aureus* agr system activates global regulator MgrA by stabilizing mRNA. *Proc. Natl. Acad. Sci. USA* **112**, 14036–14041.
45. Boisset, S., Geissmann, T., Huntzinger, E., Fechter, P., Bendridi, N., Posseko, M., Chevalier, C., Helfer, A.C., Benito, Y., Jacquier, A., et al. (2007). *Staphylococcus aureus* RNAIII coordinately represses the synthesis of virulence factors and the transcription regulator Rot by an anti-sense mechanism. *Genes Dev.* **21**, 1353–1366.
46. Le Huyen, K.B., Gonzalez, C.D., Pascreau, G., Bordeau, V., Cattoir, V., Liu, W., Bouloc, P., Felden, B., and Chabelskaya, S. (2021). A small

- regulatory RNA alters *Staphylococcus aureus* virulence by titrating RNAlIII activity. *Nucleic Acids Res.* 49, 10644–10656.
47. Jin, Y., Watt, R.M., Danchin, A., and Huang, J.d. (2009). Small noncoding RNA GcvB is a novel regulator of acid resistance in *Escherichia coli*. *BMC Genom.* 10, 165.
48. Ju, X., Fang, X., Xiao, Y., Li, B., Shi, R., Wei, C., and You, C. (2021). Small RNA GcvB Regulates Oxidative Stress Response of *Escherichia coli*. *Antioxidants* 10, 1774.
49. Pulvermacher, S.C., Stauffer, L.T., and Stauffer, G.V. (2008). The role of the small regulatory RNA GcvB in GcvB/mRNA posttranscriptional regulation of oppA and dppA in *Escherichia coli*. *FEMS Microbiol. Lett.* 281, 42–50.
50. Sharma, C.M., Darfeuille, F., Plantinga, T.H., and Vogel, J. (2007). A small RNA regulates multiple ABC transporter mRNAs by targeting C/A-rich elements inside and upstream of ribosome-binding sites. *Genes Dev.* 21, 2804–2817.
51. Westermann, A.J. (2018). Regulatory RNAs in Virulence and Host-Microbe Interactions. *Microbiol. Spectr.* 6.
52. Kim, K., Palmer, A.D., Vanderpool, C.K., and Slauch, J.M. (2019). The Small RNA PinT Contributes to PhoP-Mediated Regulation of the *Salmonella* Pathogenicity Island 1 Type III Secretion System in *Salmonella enterica* Serovar Typhimurium. *J. Bacteriol.* 201, e00312-19.
53. Palmer, A.D., Kim, K., and Slauch, J.M. (2019). PhoP-Mediated Repression of the SPI1 Type 3 Secretion System in *Salmonella enterica* Serovar Typhimurium. *J. Bacteriol.* 201, e00264-19.
54. Ortega, A.D., Gonzalo-Asensio, J., and García-del Portillo, F. (2012). Dynamics of *Salmonella* small RNA expression in non-growing bacteria located inside eukaryotic cells. *RNA Biol.* 9, 469–488.
55. Avican, K., Aldahdooh, J., Togninalli, M., Mahmud, A.K.M.F., Tang, J., Borgwardt, K.M., Rhen, M., and Fällman, M. (2021). RNA atlas of human bacterial pathogens uncovers stress dynamics linked to infection. *Nat. Commun.* 12, 3282.
56. Mulhbacher, J., Brouillette, E., Allard, M., Fortier, L.-C., Malouin, F., and Lafontaine, D.A. (2010). Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways. *PLoS Pathog.* 6, e1000865.
57. Kim, J.N., Blount, K.F., Puskarz, I., Lim, J., Link, K.H., and Breaker, R.R. (2009). Design and antimicrobial action of purine analogues that bind Guanine riboswitches. *ACS Chem. Biol.* 4, 915–927.
58. Yan, L.-H., Le Roux, A., Boyapelly, K., Lamontagne, A.-M., Archambault, M.-A., Picard-Jean, F., Lalonde-Seguin, D., St-Pierre, E., Najmanovich, R.J., Fortier, L.-C., et al. (2018). Purine analogs targeting the guanine riboswitch as potential antibiotics against *Clostridioides difficile*. *Eur. J. Med. Chem.* 143, 755–768.
59. Lee, E.R., Blount, K.F., and Breaker, R.R. (2009). Roseoflavin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression. *RNA Biol.* 6, 187–194.
60. Wang, H., Mann, P.A., Xiao, L., Gill, C., Galgoci, A.M., Howe, J.A., Villafania, A., Barbieri, C.M., Malinvern, J.C., Sher, X., et al. (2017). Dual-Targeting Small-Molecule Inhibitors of the *Staphylococcus aureus* FMN Riboswitch Disrupt Riboflavin Homeostasis in an Infectious Setting. *Cell Chem. Biol.* 24, 576–588.e6.
61. Sudarsan, N., Cohen-Chalamish, S., Nakamura, S., Emilsson, G.M., and Breaker, R.R. (2005). Thiamine pyrophosphate riboswitches are targets for the antimicrobial compound pyrithiamine. *Chem. Biol.* 12, 1325–1335.
62. Traykovska, M., Otcheva, L.A., and Penchovsky, R. (2022). Targeting TPP Riboswitches Using Chimeric Antisense Oligonucleotide Technology for Antibacterial Drug Development. *ACS Appl. Bio Mater.* 5, 4896–4902.
63. Traykovska, M., and Penchovsky, R. (2022). Targeting SAM-I Riboswitch Using Antisense Oligonucleotide Technology for Inhibiting the Growth of *Staphylococcus aureus* and *Listeria monocytogenes*. *Antibiotics* 11, 1662.
64. Ellinger, E., Chauvier, A., Romero, R.A., Liu, Y., Ray, S., and Walter, N.G. (2023). Riboswitches as therapeutic targets: Promise of a new era of antibiotics. *Expert Opin. Ther. Targets* 27, 433–445.
65. Petroni, E., Esnault, C., Tetreault, D., Dale, R.K., Storz, G., and Adams, P.P. (2023). Extensive diversity in RNA termination and regulation revealed by transcriptome mapping for the Lyme pathogen *Borrelia burgdorferi*. *Nat. Commun.* 14, 3931.
66. Mandell, Z.F., Vishwakarma, R.K., Yakhnin, H., Murakami, K.S., Kashlev, M., and Babitzke, P. (2022). Comprehensive transcription terminator atlas for *Bacillus subtilis*. *Nat. Microbiol.* 7, 1918–1931.
67. Popella, L., Jung, J., Do, P.T., Hayward, R.J., Barquist, L., and Vogel, J. (2022). Comprehensive analysis of PNA-based antisense antibiotics targeting various essential genes in uropathogenic *Escherichia coli*. *Nucleic Acids Res.* 50, 6435–6452.
68. Sparmann, A., and Vogel, J. (2023). RNA-based medicine: from molecular mechanisms to therapy. *EMBO J.* e114760.
69. Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P.F., and Yu, T. (2023). CRISPR/Cas9 therapeutics: progress and prospects. *Signal Transduct. Targeted Ther.* 8, 36.
70. Roy, S., Naha, S., Rao, A., and Basu, S. (2021). CRISPR-Cas system, antibiotic resistance and virulence in bacteria: Through a common lens. *Prog. Mol. Biol. Transl. Sci.* 178, 123–174.
71. Guan, R., Chu, D., Han, X., Miao, X., and Li, H. (2021). Advances in the Development of Microbial Double-Stranded RNA Production Systems for Application of RNA Interference in Agricultural Pest Control. *Front. Bioeng. Biotechnol.* 9, 753790.
72. Morens, D.M., and Fauci, A.S. (2020). Emerging Pandemic Diseases: How We Got to COVID-19. *Cell* 182, 1077–1092.
73. Dethoff, E.A., Chugh, J., Mustoe, A.M., and Al-Hashimi, H.M. (2012). Functional complexity and regulation through RNA dynamics. *Nature* 482, 322–330.
74. Jones, C.P., and Ferré-D'Amare, A.R. (2017). Long-Range Interactions in Riboswitch Control of Gene Expression. *Annu. Rev. Biophys.* 46, 455–481.
75. Meyer, M.M. (2016). The Role of mRNA Structure in Bacterial Translational Regulation. *Wiley Interdiscip. Rev. RNA* 8.
76. Ganser, L.R., Kelly, M.L., Herschlag, D., and Al-Hashimi, H.M. (2019). The roles of structural dynamics in the cellular functions of RNAs. *Nat. Rev. Mol. Cell Biol.* 20, 474–489.
77. Chełkowska-Pauszek, A., Kosiński, J.G., Marciniak, K., Wysocka, M., Bąkowska-Żywicka, K., and Żywicki, M. (2021). The Role of RNA Secondary Structure in Regulation of Gene Expression in Bacteria. *Int. J. Mol. Sci.* 22, 7845.
78. Chen, J., Coakley, A., O'Connor, M., Petrov, A., O'Leary, S.E., Atkins, J.F., and Puglisi, J.D. (2015). Coupling of mRNA Structure Rearrangement to Ribosome Movement during Bypassing of Non-coding Regions. *Cell* 163, 1267–1280.
79. Wu, M.T.-P., and D'Souza, V. (2020). Alternate RNA Structures. *Cold Spring Harbor Perspect. Biol.* 12, a032425.
80. Liu, B., Shi, H., and Al-Hashimi, H.M. (2021). Developments in solution-state NMR yield broader and deeper views of the dynamic ensembles of nucleic acids. *Curr. Opin. Struct. Biol.* 70, 16–25.
81. Ditzler, M.A., Rueda, D., Mo, J., Häkansson, K., and Walter, N.G. (2008). A rugged free energy landscape separates multiple functional RNA folds throughout denaturation. *Nucleic Acids Res.* 36, 7088–7099.
82. Bonilla, S.L., Vicens, Q., and Kieft, J.S. (2022). Cryo-EM reveals an entangled kinetic trap in the folding of a catalytic RNA. *Sci. Adv.* 8, eabq4144.
83. Kramer, F.R., and Mills, D.R. (1981). Secondary structure formation during RNA synthesis. *Nucleic Acids Res.* 9, 5109–5124.
84. Lai, D., Proctor, J.R., and Meyer, I.M. (2013). On the importance of co-transcriptional RNA structure formation. *RNA* 19, 1461–1473.

85. Pan, T., and Sosnick, T. (2006). RNA folding during transcription. *Annu. Rev. Biophys. Biomol. Struct.* 35, 161–175.
86. Bar-Nahum, G., Epshtain, V., Ruckenstein, A.E., Rafikov, R., Mustaev, A., and Nudler, E. (2005). A ratchet mechanism of transcription elongation and its control. *Cell* 120, 183–193.
87. McDowell, J.C., Roberts, J.W., Jin, D.J., and Gross, C. (1994). Determination of intrinsic transcription termination efficiency by RNA polymerase elongation rate. *Science* 266, 822–825.
88. Saldi, T., Riemondy, K., Erickson, B., and Bentley, D.L. (2021). Alternative RNA structures formed during transcription depend on elongation rate and modify RNA processing. *Mol. Cell* 81, 1789–1801.e5.
89. Scull, C.E., Dandpat, S.S., Romero, R.A., and Walter, N.G. (2020). Transcriptional Riboswitches Integrate Timescales for Bacterial Gene Expression Control. *Front. Mol. Biosci.* 7, 607158.
90. Vogel, U., and Jensen, K.F. (1994). The RNA chain elongation rate in *Escherichia coli* depends on the growth rate. *J. Bacteriol.* 176, 2807–2813.
91. Landick, R. (2021). Transcriptional Pausing as a Mediator of Bacterial Gene Regulation. *Annu. Rev. Microbiol.* 75, 291–314.
92. Alexander, R.D., Innocente, S.A., Barrass, J.D., and Beggs, J.D. (2010). Splicing-dependent RNA polymerase pausing in yeast. *Mol. Cell* 40, 582–593.
93. Reimer, K.A., Mimoso, C.A., Adelman, K., and Neugebauer, K.M. (2021). Co-transcriptional splicing regulates 3' end cleavage during mammalian erythropoiesis. *Mol. Cell* 81, 998–1012.e7.
94. Oesterreich, F.C., Herzel, L., Straube, K., Hujer, K., Howard, J., and Neugebauer, K.M. (2016). Splicing of Nascent RNA Coincides with Intron Exit from RNA Polymerase II. *Cell* 165, 372–381.
95. Zeng, Y., Fair, B.J., Zeng, H., Krishnamohan, A., Hou, Y., Hall, J.M., Ruthenburg, A.J., Li, Y.I., and Staley, J.P. (2022). Profiling lariat intermediates reveals genetic determinants of early and late co-transcriptional splicing. *Mol. Cell* 82, 4681–4699.e8.
96. Maudlin, I.E., and Beggs, J.D. (2019). Spt5 modulates co-transcriptional spliceosome assembly in *Saccharomyces cerevisiae*. *RNA* 25, 1298–1310.
97. Carnesecchi, J., Boumpas, P., van Nierop y Sanchez, P., Domsch, K., Pinto, H.D., Borges Pinto, P., and Lohmann, I. (2022). The Hox transcription factor Ultrabithorax binds RNA and regulates co-transcriptional splicing through an interplay with RNA polymerase II. *Nucleic Acids Res.* 50, 763–783.
98. Gusarov, I., and Nudler, E. (1999). The mechanism of intrinsic transcription termination. *Mol. Cell* 3, 495–504.
99. Yakhnin, A.V., and Babitzke, P. (2010). Mechanism of NusG-stimulated pausing, hairpin-dependent pause site selection and intrinsic termination at overlapping pause and termination sites in the *Bacillus subtilis* trp leader. *Mol. Microbiol.* 76, 690–705.
100. Chauvier, A., Ajmera, P., Yadav, R., and Walter, N.G. (2021). Dynamic competition between a ligand and transcription factor NusA governs riboswitch-mediated transcription regulation. *Proc. Natl. Acad. Sci. USA* 118, e2109026118.
101. Yakhnin, A.V., and Babitzke, P. (2002). NusA-stimulated RNA polymerase pausing and termination participates in the *Bacillus subtilis* trp operon attenuation mechanism invitro. *Proc. Natl. Acad. Sci. USA* 99, 11067–11072.
102. Yakhnin, A.V., Yakhnin, H., and Babitzke, P. (2006). RNA polymerase pausing regulates translation initiation by providing additional time for TRAP-RNA interaction. *Mol. Cell* 24, 547–557.
103. Wong, T., Sosnick, T.R., and Pan, T. (2005). Mechanistic insights on the folding of a large ribozyme during transcription. *Biochemistry* 44, 7535–7542.
104. Wong, T.N., Sosnick, T.R., and Pan, T. (2007). Folding of noncoding RNAs during transcription facilitated by pausing-induced nonnative structures. *Proc. Natl. Acad. Sci. USA* 104, 17995–18000.
105. Fan, J., Leroux-Coyau, M., Savery, N.J., and Strick, T.R. (2016). Reconstruction of bacterial transcription-coupled repair at single-molecule resolution. *Nature* 536, 234–237.
106. Martinez, B., Bharati, B.K., Epshtain, V., and Nudler, E. (2022). Pervasive Transcription-coupled DNA repair in *E. coli*. *Nat. Commun.* 13, 1702.
107. Bharati, B.K., Gowder, M., Zheng, F., Alzoubi, K., Svetlov, V., Kamarthapu, V., Weaver, J.W., Epshtain, V., Vasilyev, N., Shen, L., et al. (2022). Crucial role and mechanism of transcription-coupled DNA repair in bacteria. *Nature* 604, 152–159.
108. Chatterjee, S., Chauvier, A., Dandpat, S.S., Artsimovitch, I., and Walter, N.G. (2021). A translational riboswitch coordinates nascent transcription–translation coupling. *Proc. Natl. Acad. Sci. USA* 118, e2023426118.
109. Johnson, G.E., Lalanne, J.-B., Peters, M.L., and Li, G.-W. (2020). Functionally uncoupled transcription-translation in *Bacillus subtilis*. *Nature* 585, 124–128.
110. Proshkin, S., Rahmouni, A.R., Mironov, A., and Nudler, E. (2010). Cooperation between translating ribosomes and RNA polymerase in transcription elongation. *Science* 328, 504–508.
111. Woodson, S.A. (2002). Folding mechanisms of group I ribozymes: role of stability and contact order. *Biochem. Soc. Trans.* 30, 1166–1169.
112. Pan, T., Artsimovitch, I., Fang, X.W., Landick, R., and Sosnick, T.R. (1999). Folding of a large ribozyme during transcription and the effect of the elongation factor NusA. *Proc. Natl. Acad. Sci. USA* 96, 9545–9550.
113. Winkler, W.C., Cohen-Chalamish, S., and Breaker, R.R. (2002). An mRNA structure that controls gene expression by binding FMN. *Proc. Natl. Acad. Sci. USA* 99, 15908–15913.
114. Mironov, A.S., Gusarov, I., Rafikov, R., Lopez, L.E., Shatalin, K., Kreneva, R.A., Perumov, D.A., and Nudler, E. (2002). Sensing small molecules by nascent RNA: a mechanism to control transcription in bacteria. *Cell* 111, 747–756.
115. Wickiser, J.K., Winkler, W.C., Breaker, R.R., and Crothers, D.M. (2005). The speed of RNA transcription and metabolite binding kinetics operate an FMN riboswitch. *Mol. Cell* 18, 49–60.
116. Lai, W.-J.C., Kayedkhordeh, M., Cornell, E.V., Farah, E., Bellaousov, S., Rietmeijer, R., Salsi, E., Mathews, D.H., and Ermolenko, D.N. (2018). mRNAs and lncRNAs intrinsically form secondary structures with short end-to-end distances. *Nat. Commun.* 9, 4328.
117. Chauvier, A., St-Pierre, P., Nadon, J.-F., Hien, E.D.M., Pérez-González, C., Eschbach, S.H., Lamontagne, A.-M., Penedo, J.C., and Lafontaine, D.A. (2021). Monitoring RNA dynamics in native transcriptional complexes. *Proc. Natl. Acad. Sci. USA* 118, e2106564118.
118. Helmling, C., Wacker, A., Wolfinger, M.T., Hofacker, I.L., Hengesbach, M., Fürtg, B., and Schwalbe, H. (2017). NMR Structural Profiling of Transcriptional Intermediates Reveals Riboswitch Regulation by Metastable RNA Conformations. *J. Am. Chem. Soc.* 139, 2647–2656.
119. Helmling, C., Klötzner, D.P., Sochor, F., Mooney, R.A., Wacker, A., Landick, R., Fürtg, B., Heckel, A., and Schwalbe, H. (2018). Life times of metastable states guide regulatory signaling in transcriptional riboswitches. *Nat. Commun.* 9, 944.
120. Steinert, H., Sochor, F., Wacker, A., Buck, J., Helmling, C., Hiller, F., Keyhani, S., Noeske, J., Grimm, S., Rudolph, M.M., et al. (2017). Pausing guides RNA folding to populate transiently stable RNA structures for riboswitch-based transcription regulation. *Elife* 6, e21297.
121. Turowski, T.W., Petfalski, E., Goddard, B.D., French, S.L., Helwak, A., and Tollervey, D. (2020). Nascent Transcript Folding Plays a Major Role in Determining RNA Polymerase Elongation Rates. *Mol. Cell* 79, 488–503.e11.
122. Epshtain, V., Cardinale, C.J., Ruckenstein, A.E., Borukhov, S., and Nudler, E. (2007). An allosteric path to transcription termination. *Mol. Cell* 28, 991–1001.
123. Santangelo, T.J., and Artsimovitch, I. (2011). Termination and antitermination: RNA polymerase runs a stop sign. *Nat. Rev. Microbiol.* 9, 319–329.

124. Chauvier, A., Picard-Jean, F., Berger-Dancause, J.-C., Bastet, L., Naghdi, M.R., Dubé, A., Turcotte, P., Perreault, J., and Lafontaine, D.A. (2017). Transcriptional pausing at the translation start site operates as a critical checkpoint for riboswitch regulation. *Nat. Commun.* 8, 13892.
125. Widom, J.R., Nedialkov, Y.A., Rai, V., Hayes, R.L., Brooks, C.L., Artsimovitch, I., and Walter, N.G. (2018). Ligand Modulates Cross-Coupling between Riboswitch Folding and Transcriptional Pausing. *Mol. Cell* 72, 541–552.e6.
126. Tetone, L.E., Friedman, L.J., Osborne, M.L., Ravi, H., Kyzer, S., Stumper, S.K., Mooney, R.A., Landick, R., and Gelles, J. (2017). Dynamics of GreB-RNA polymerase interaction allow a proofreading accessory protein to patrol for transcription complexes needing rescue. *Proc. Natl. Acad. Sci. USA* 114, E1081–E1090.
127. Friedman, L.J., and Gelles, J. (2012). Mechanism of transcription initiation at an activator-dependent promoter defined by single-molecule observation. *Cell* 148, 679–689.
128. Rodgers, M.L., and Woodson, S.A. (2019). Transcription Increases the Cooperativity of Ribonucleoprotein Assembly. *Cell* 179, 1370–1381.e12.
129. Duss, O., Stepanyuk, G.A., Grot, A., O'Leary, S.E., Puglisi, J.D., and Williamson, J.R. (2018). Real-time assembly of ribonucleoprotein complexes on nascent RNA transcripts. *Nat. Commun.* 9, 5087.
130. Duss, O., Stepanyuk, G.A., Puglisi, J.D., and Williamson, J.R. (2019). Transient Protein-RNA Interactions Guide Nascent Ribosomal RNA Folding. *Cell* 179, 1357–1369.e16.
131. Kim, H., Abeyasinghe, S.C., Chen, K., Mayerle, M., Ragunathan, K., Luthey-Schulten, Z., Ha, T., and Woodson, S.A. (2014). Protein-guided RNA dynamics during early ribosome assembly. *Nature* 506, 334–338.
132. Rodgers, M.L., O'Brien, B., and Woodson, S.A. (2023). Small RNAs and Hfq capture unfolded RNA target sites during transcription. *Mol. Cell* 83, 1489–1501.e5.
133. Kohler, R., Mooney, R.A., Mills, D.J., Landick, R., and Cramer, P. (2017). Architecture of a transcribing-translating expressome. *Science* 356, 194–197.
134. O'Reilly, F.J., Xue, L., Graziadei, A., Sinn, L., Lenz, S., Tegunov, D., Blötz, C., Singh, N., Hagen, W.J.H., Cramer, P., et al. (2020). In-cell architecture of an actively transcribing-translating expressome. *Science* 369, 554–557.
135. Demo, G., Rasouly, A., Vasilyev, N., Svetlov, V., Loveland, A.B., Diaz-Avalos, R., Grigorieff, N., Nudler, E., and Korostelev, A.A. (2017). Structure of RNA polymerase bound to ribosomal 30S subunit. *Elife* 6, e28560.
136. Webster, M.W., and Weixlbaumer, A. (2021). Macromolecular assemblies supporting transcription-translation coupling. *Transcription* 12, 103–125.
137. Bastet, L., Chauvier, A., Singh, N., Lussier, A., Lamontagne, A.-M., Prévost, K., Massé, E., Wade, J.T., and Lafontaine, D.A. (2017). Translational control and Rho-dependent transcription termination are intimately linked in riboswitch regulation. *Nucleic Acids Res.* 45, 7474–7486.
138. Chakchhuak, P.I.R., and Sen, R. (2022). *In vivo* regulation of bacterial Rho-dependent transcription termination by the nascent RNA. *J. Biol. Chem.* 298, 102001.
139. Chauvier, A., Porta, J.C., Deb, I., Ellinger, E., Meze, K., Frank, A.T., Ohi, M.D., and Walter, N.G. (2023). Structural basis for control of bacterial RNA polymerase pausing by a riboswitch and its ligand. *Nat. Struct. Mol. Biol.* 30, 902–913.
140. Dey, S., Batisse, C., Shukla, J., Webster, M.W., Takacs, M., Saint-André, C., and Weixlbaumer, A. (2022). Structural insights into RNA-mediated transcription regulation in bacteria. *Mol. Cell* 82, 3885–3900.e10.
141. Yadav, R., Widom, J.R., Chauvier, A., and Walter, N.G. (2022). An anionic ligand snap-locks a long-range interaction in a magnesium-folded riboswitch. *Nat. Commun.* 13, 207.
142. Maziuk, B., Ballance, H.I., and Wolozin, B. (2017). Dysregulation of RNA Binding Protein Aggregation in Neurodegenerative Disorders. *Front. Mol. Neurosci.* 10, 89.
143. Liu, E.Y., Cali, C.P., and Lee, E.B. (2017). RNA metabolism in neurodegenerative disease. *Dis. Model. Mech.* 10, 509–518.
144. Ayala, Y.M., and Nguyen, A.D. (2021). RNA-Based Therapies for Neurodegenerative Diseases. *Mo. Med.* 118, 340–345.
145. Markelova, N., Glazunova, O., Alikina, O., Panyukov, V., Shavkunov, K., and Ozoline, O. (2021). Suppression of *Escherichia coli* Growth Dynamics via RNAs Secreted by Competing Bacteria. *Front. Mol. Biosci.* 8, 609979.
146. Karlsson, J., Eichner, H., Andersson, C., Jacobsson, S., and Loh, E. (2020). Novel hypercapsulation RNA thermosensor variants in *Neisseria meningitidis* and their association with invasive meningococcal disease: a genetic and phenotypic investigation and molecular epidemiological study. *Lancet. Microbe* 1, e319–e327.
147. Pinzaru, A.M., and Tavazoie, S.F. (2023). Transfer RNAs as dynamic and critical regulators of cancer progression. *Nat. Rev. Cancer* 23, 746–761.
148. Zhao, Y., Li, X., Ye, C., Huang, C., Lv, X., and Li, J. (2023). The biogenesis, mechanism and function of the tRNA-derived small RNA (tsRNA): a review compared with microRNA. *Am. J. Cancer Res.* 13, 1656–1666.
149. Van Bortle, K., Marciano, D.P., Liu, Q., Chou, T., Lipchik, A.M., Gollapudi, S., Geller, B.S., Monte, E., Kamakaka, R.T., and Snyder, M.P. (2022). A cancer-associated RNA polymerase III identity drives robust transcription and expression of snaR-A noncoding RNA. *Nat. Commun.* 13, 3007.
150. Galka-Marciniak, P., Urbanek-Trzeciak, M.O., Nawrocka, P.M., and Koźłowski, P. (2021). A pan-cancer atlas of somatic mutations in miRNA biogenesis genes. *Nucleic Acids Res.* 49, 601–620.
151. Hussen, B.M., Hidayat, H.J., Salihi, A., Sabir, D.K., Taheri, M., and Ghaffouri-Fard, S. (2021). MicroRNA: A signature for cancer progression. *Bio-med. Pharmacother.* 138, 111528.
152. Poolman, B. (2023). Physicochemical homeostasis in bacteria. *FEMS Microbiol. Rev.* 47, fua033.
153. Pontes, M.H., Yeom, J., and Groisman, E.A. (2016). Reducing Ribosome Biosynthesis Promotes Translation during Low Mg(2+) Stress. *Mol. Cell* 64, 480–492.
154. Groisman, E.A., and Chan, C. (2021). Cellular Adaptations to Cytoplasmic Mg²⁺ Limitation. *Annu. Rev. Microbiol.* 75, 649–672.
155. Reining, A., Nozinovic, S., Schlepckow, K., Buhr, F., Fürtig, B., and Schwalbe, H. (2013). Three-state mechanism couples ligand and temperature sensing in riboswitches. *Nature* 499, 355–359.
156. Mollocana-Lara, E.C., Ni, M., Agathos, S.N., and Gonzales-Zubiate, F.A. (2021). The infinite possibilities of RNA therapeutics. *J. Ind. Microbiol. Biotechnol.* 48, kuab063.
157. Winkle, M., El-Daly, S.M., Fabbri, M., and Calin, G.A. (2021). Noncoding RNA therapeutics — challenges and potential solutions. *Nat. Rev. Drug Discov.* 20, 629–651.
158. Cardinale, C.J., Washburn, R.S., Tadigotla, V.R., Brown, L.M., Gottesman, M.E., and Nudler, E. (2008). Termination factor Rho and its cofactors NusA and NusG silence foreign DNA in *E. coli*. *Science* 320, 935–938.
159. Braddé, S., Nourmohammad, A., Goyal, S., and Balasubramanian, V. (2020). The size of the immune repertoire of bacteria. *Proc. Natl. Acad. Sci. USA* 117, 5144–5151.
160. Schelling, M.A., and Sashital, D.G. (2020). An adaptable defense. *Elife* 9, e56122.
161. Paunovska, K., Loughrey, D., and Dahlman, J.E. (2022). Drug delivery systems for RNA therapeutics. *Nat. Rev. Genet.* 23, 265–280.
162. Ranjbar, S., Zhong, X.-B., Manautou, J., and Lu, X. (2023). A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics. *Adv. Drug Deliv. Rev.* 201, 115052.
163. Biedenbänder, T., de Jesus, V., Schmidt-Dengler, M., Helm, M., Corzilius, B., and Fürtig, B. (2022). RNA modifications stabilize the tertiary structure of tRNAMet by locally increasing conformational dynamics. *Nucleic Acids Res.* 1, gkac040.

164. Boo, S.H., and Kim, Y.K. (2020). The emerging role of RNA modifications in the regulation of mRNA stability. *Exp. Mol. Med.* 52, 400–408.
165. Yu, A.M., Gasper, P.M., Cheng, L., Lai, L.B., Kaur, S., Gopalan, V., Chen, A.A., and Lucks, J.B. (2021). Computationally reconstructing cotranscriptional RNA folding from experimental data reveals rearrangement of non-native folding intermediates. *Mol. Cell* 81, 870–883.e10.
166. Xue, A.Y., Yu, A.M., Lucks, J.B., and Bagheri, N. (2019). DUETT quantitatively identifies known and novel events in nascent RNA structural dynamics from chemical probing data. *Bioinformatics* 35, 5103–5112.
167. Wang, X., Terashi, G., and Kihara, D. (2023). CryoREAD: *de novo* structure modeling for nucleic acids in cryo-EM maps using deep learning. *Nat. Methods* 20, 1739–1747.
168. Tānasie, A.R., Kerpedjiev, P., Hammer, S., and Badelt, S. (2023). DrForna: visualization of cotranscriptional folding. *Bioinformatics* 39, btad555.
169. Baquero, F., and Levin, B.R. (2020). Proximate and ultimate causes of the bactericidal action of antibiotics. *Nat. Rev. Microbiol.* 19, 123–132.
170. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature* 596, 583–589.
171. Hekkelman, M.L., de Vries, I., Joosten, R.P., and Perrakis, A. (2023). AlphaFill: enriching AlphaFold models with ligands and cofactors. *Nat. Methods* 20, 205–213.
172. Schneider, B., Sweeney, B.A., Bateman, A., Cerny, J., Zok, T., and Szachniuk, M. (2023). When will RNA get its AlphaFold moment? *Nucleic Acids Res.* 51, 9522–9532.
173. Incarnato, D., Morandi, E., Anselmi, F., Simon, L.M., Basile, G., and Oliviero, S. (2017). In vivo probing of nascent RNA structures reveals principles of cotranscriptional folding. *Nucleic Acids Res.* 45, 9716–9725.
174. Watters, K.E., Abbott, T.R., and Lucks, J.B. (2016). Simultaneous characterization of cellular RNA structure and function with in-cell SHAPE-Seq. *Nucleic Acids Res.* 44, e12.
175. Yu, G., Liu, Y., Li, Z., Deng, S., Wu, Z., Zhang, X., Chen, W., Yang, J., Chen, X., and Yang, J.-R. (2023). Genome-wide probing of eukaryotic nascent RNA structure elucidates cotranscriptional folding and its anti-mutagenic effect. *Nat. Commun.* 14, 5853.
176. Kwok, C.K., Ding, Y., Tang, Y., Assmann, S.M., and Bevilacqua, P.C. (2013). Determination of *in vivo* RNA structure in low-abundance transcripts. *Nat. Commun.* 4, 2971.
177. Olson, S.W., Turner, A.-M.W., Arney, J.W., Saleem, I., Weidmann, C.A., Margolis, D.M., Weeks, K.M., and Mustoe, A.M. (2022). Discovery of a large-scale, cell-state-responsive allosteric switch in the 7SK RNA using DANCE-MaP. *Mol. Cell* 82, 1708–1723.e10.
178. Torino, S., Dhurandhar, M., Stroobants, A., Claessens, R., and Efremov, R.G. (2023). Time-resolved cryo-EM using a combination of droplet microfluidics with on-demand jetting. *Nat. Methods* 20, 1400–1408.
179. Carbone, C.E., Loveland, A.B., Gamper, H.B., Hou, Y.-M., Demo, G., and Korostelev, A.A. (2021). Time-resolved cryo-EM visualizes ribosomal translocation with EF-G and GTP. *Nat. Commun.* 12, 7236.
180. Zeller, M.J., Favorov, O., Li, K., Nuthanakanti, A., Hussein, D., Michaud, A., Lafontaine, D.A., Busan, S., Serganov, A., Aubé, J., and Weeks, K.M. (2022). SHAPE-enabled fragment-based ligand discovery for RNA. *Proc. Natl. Acad. Sci. USA* 119, e2122660119.